B
35.11
-1.29 (-3.54%)
| 前收盘价格 | 36.40 |
| 收盘价格 | 35.98 |
| 成交量 | 1,191,232 |
| 平均成交量 (3个月) | 2,988,345 |
| 市值 | 6,677,535,744 |
| 价格/销量 (P/S) | 31.21 |
| 52周波幅 | |
| 利润日期 | 30 Apr 2025 - 5 May 2025 |
| 营业毛利率 | -241.44% |
| 营业利益率 (TTM) | -3,762.90% |
| 稀释每股收益 (EPS TTM) | -2.88 |
| 季度收入增长率 (YOY) | 237.10% |
| 流动比率 (MRQ) | 4.67 |
| 营业现金流 (OCF TTM) | -520.73 M |
| 杠杆自由现金流 (LFCF TTM) | -288.27 M |
| 资产报酬率 (ROA TTM) | -47.83% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | BridgeBio Pharma, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
2.0
| 分析师共识 | 5.0 |
| 内部交易活动 | 1.5 |
| 价格波动 | -0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 2.00 |
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 5.41% |
| 机构持股比例 | 91.10% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Kohlberg Kravis Roberts & Co. L.P. | 31 Dec 2024 | 25,260,971 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 95.00 (Cantor Fitzgerald, 170.58%) | 购买 |
| 中 | 50.00 (42.41%) | |
| 低 | 49.00 (Citigroup, 39.56%) | 购买 |
| 49.00 (HC Wainwright & Co., 39.56%) | 购买 | |
| 平均值 | 57.50 (63.77%) | |
| 总计 | 6 购买 | |
| 平均价格@调整类型 | 35.74 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Redburn Atlantic | 31 Mar 2025 | 50.00 (42.41%) | 购买 | 35.11 |
| JP Morgan | 24 Mar 2025 | 50.00 (42.41%) | 购买 | 37.22 |
| Cantor Fitzgerald | 21 Feb 2025 | 95.00 (170.58%) | 购买 | 36.85 |
| Citigroup | 21 Feb 2025 | 49.00 (39.56%) | 购买 | 36.85 |
| Scotiabank | 21 Feb 2025 | 52.00 (48.11%) | 购买 | 36.85 |
| 12 Feb 2025 | 49.00 (39.56%) | 购买 | 31.95 | |
| HC Wainwright & Co. | 13 Feb 2025 | 49.00 (39.56%) | 购买 | 31.56 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合